Alzamend Neuro, INC. (ALZN) SEC Filings — 2025

Filings

• Alzamend Neuro's Losses Mount Amid R&D Surge, Going Concern Doubts — 10-Q · Dec 9, 2025
• Alzamend Neuro Files 8-K — 8-K · Nov 18, 2025
• Alzamend Neuro Files 8-K with Corporate Updates — 8-K · Oct 14, 2025
• Alzamend Neuro Files 8-K on Equity Sales — 8-K · Oct 9, 2025
• Alzamend Neuro Files 8-K on Equity Sales — 8-K · Sep 25, 2025
• Alzamend Neuro's R&D Soars, Net Loss Triples Amid Reverse Splits — 10-Q · Sep 10, 2025
• Alzamend Neuro Files 8-K on Equity Sales — 8-K · Aug 1, 2025
• Alzamend Neuro Files 8-K on Operations — 8-K · Jul 23, 2025
• Alzamend Neuro Continues R&D Focus, Zero Revenue in FY25 — 10-K · Jul 22, 2025
• Alzamend Neuro Files 8-K with Corporate Updates — 8-K · Jul 9, 2025
• Alzamend Neuro Files 8-K with Corporate Updates — 8-K · May 8, 2025
• Alzamend Neuro Files 8-K on Shareholder Votes and Financials — 8-K · Apr 25, 2025
• Alzamend Neuro Files S-1/A Amendment — S-1/A · Mar 27, 2025
• Alzamend Neuro Files Proxy Statement Amendment — DEFA14A · Mar 19, 2025
• Alzamend Neuro Files Proxy Statement Amendment — DEFA14A · Mar 17, 2025
• Alzamend Neuro Proxy Statement Filed for April 25 Meeting — DEF 14A · Mar 13, 2025
• Alzamend Neuro Files 10-Q, Details Financials — 10-Q · Mar 10, 2025
• Alzamend Neuro Files 8-K for Bylaws, Exhibits — 8-K · Mar 3, 2025
• Alzamend Neuro Files 8-K on Agreements and Equity Sales — 8-K · Feb 28, 2025